{"denoms":[{"counts":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"152"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed or refractory (r/r) B-cell indolent non-Hodgkin lymphoma (iNHL) subtype of follicular lymphoma (FL) received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day intravenously (IV) and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0.","id":"BG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of marginal zone lymphoma (MZL) received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"BG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"101"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"51"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.9","value":"59"},{"groupId":"BG001","spread":"9.6","value":"63"},{"groupId":"BG002","spread":"10.0","value":"60.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"66"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"86"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"142"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"140"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Other or More Than One Race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Asian"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"142"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"10"}]}],"title":"France"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"The Safety Analysis Set was defined as all participants treated with any dose of study drug."}